Perosphere is a specialty pharmaceutical company with internationally recognized drug delivery expertise.

Perosphere's lead drug candidate is a reversal agent for new oral anticoagulants ("NOACs"), such as Daiichi Sankyo Co., Ltd.'s Lixiana® (edoxaban), Boehringer Ingelheim GmbH's Pradaxa® (dabigatran), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban), and Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban). There is currently no approved reversal agent for these NOACs.